78 results about "Rituximab" patented technology

This invention provides the use of a combination of CCI-779 and rituximab in the treatment of non-Hodgkin's lymphoma.

This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.

The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-κB, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.

The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.

The invention provides a site-directed mutated rituximab containing unnatural amino acid markers and a method for conjugating the rituximab by site-directed mutation and site-directed micro-molecules. The method includes the steps: leading unnatural amino acid into rituximab genes by genetic codon extension technology in a site-directed manner; performing site-directed connection by the aid of the unnatural amino acid and modifiers such as poly-difunctional connecting arms DIBO-DOTA; further realizing site-directed conjugating of the rituximab and radioactive isotope such as Cu64 through DOBO-DOTA. The invention further relates to an application of site-directed conjugated micro-molecule rituximab as development, tracing and therapeutic radio-immunity conjugate.

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, or systemic lupus erythematosus.

A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.

Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

A composite medicine for treating B-cell leucoma is prepared from rituximab and suberoylanilide hydroxamic acid (SAHA). Its advantages are obvious synergistic effect, high curative effect and low cost.

The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23⁺ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab. Patients with poor prognostic markers include, for example, patients that overexpress ZAP70, CD38, β2-microglobulin and/or soluble CD23.

The invention discloses a chimeric antigen receptor containing truncated CD20 molecules. The amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO. 2, and the nucleotide sequenceencoding the chimeric antigen receptor is shown in SEQ ID NO. 1; the chimeric antigen receptor comprises leader peptides, ScFv, a hinge region and a transmembrane region, immunoreceptor tyrosine activation motifs, an internal ribosome entry site (IRES) and tCD20. The invention also discloses a lentiviral vector, which comprises the nucleotide sequence encoding the chimeric antigen receptor. The invention further discloses immune cells capable of expressing the chimeric antigen receptor. The chimeric antigen receptor containing the truncated CD20 molecules can effectively kill antigen-positivetumor cells and does not have toxic and side effects on the negative cells after being expressed in the immune cells; the tCD20 carried by the chimeric antigen receptor not only can be used as tag peptide for detecting CAR expression, but also can be fed with a scavenging antibody such as rituximab after tumor cells are killed, therefore, CAR-T cells are removed, and the clinical use safety is guaranteed.

A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures to optimize the expression is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of the multi-replicon single vector system for producing Rituximab in plant cells.

The invention discloses a protein stationary phase modification open tubular column and application of the protein stationary phase modification open tubular column to monoclonal antibody charge isomer separation. The open tubular column is prepared through the following steps that PDDA is fixed on the inner wall of a capillary tube by an electrostatic self-assembly method; then, protein is adsorbed on the PDDA surface through electrostatic self assembly; the protein stationary phase modification open tubular column is obtained. The open tubular column shows specific selectivity on monoclonal antibody charge isomers. Seven kinds of different-form charge isomers of cetuximab are successfully separated; two alkaline isomers and one acid isomer of the rituximab and two alkaline charge isomers and four acid isomers of trastuzumab are successfully separated from main peaks.

The invention discloses an application of indocyanine green-rituximab in preparation of a breast cancer sentinel node tracer. When sentinel node biopsy is carried out via an indocyanine green-rituximab coupled specific tracer, since the specific tracer only fluorescently develops the sentinel node and develops no secondary lymph node, the sentinel node does not need to be found along the fluorescently developed lymphatic in the biopsy, the position of the fluorescently developed sentinel node is detected by an infrared fluorescent development system in a surgery, and the sentinel node positioned by fluorescent development is directly dissected and detected after dissecting and dissociating the peripheral tissues of the sentinel node, so as to avoid the situations of leak detection of the sentinel node and fluorescent development pollution of the peripheral tissues.

The invention discloses a rituximab/graphene oxide composite antibody as well as a preparation method and an application thereof. The rituximab/graphene oxide composite antibody consists of rituximab and graphene oxide, wherein the rituximab and the graphene oxide are linked by virtue of a non-covalent bonds, so that the composite antibody is formed; and an antineoplastic biological reaction can be enhanced greatly. Compared with the rituximab which has a slight inhibitory effect in vitro, the rituximab/graphene oxide composite antibody can directly kill lymphoma cells.

The invention discloses a compound of Fab segment of anti-cancer drug Rituximab and CD20 antigen epitope peptide, which also provides the preparing method of compound and three-dimensional crystal structure of compound and application, wherein the three-dimensional crystal structure of compound displays the key residue interacted between Rituximab and antigen epitope peptide, which provides theoretical base for higher affinity and specificity antibody; the CD20 antigen epitope peptide displays peculiar ring-shaped structure, which is fit for sieving new antibody of epitope.